Arcutis Biotherapeutics, Inc. (ARQT) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 10 Buy, 2 Hold.
The consensus price target is $33.33 (low: $29.00, high: $37.00), representing an upside of 32.8% from the current price $25.09.
Analysts estimate Earnings Per Share (EPS) of $-1.32 and revenue of $0.19B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.16 vs est $-1.32 (beat +12.3%). 2025: actual $-0.13 vs est $-0.18 (beat +29.6%). Analyst accuracy: 72%.
ARQT Stock — 12-Month Price Forecast
$33.33
▲ +32.84% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Arcutis Biotherapeutics, Inc., the average price target is $33.33, with a high forecast of $37.00, and a low forecast of $29.00.
The average price target represents a +32.84% change from the last price of $25.09.
Highest Price Target
$37.00
Average Price Target
$33.33
Lowest Price Target
$29.00
ARQT Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Arcutis Biotherapeutics, Inc. in the past 3 months
EPS Estimates — ARQT
72%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.16
vs Est –$1.32
▲ 14.0% off
2025
Actual –$0.13
vs Est –$0.18
▲ 42.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ARQT
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.197B
vs Est $0.185B
▲ 5.6% off
2025
Actual $0.376B
vs Est $0.360B
▲ 4.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
